ES|EN
Skip to content
se habla de ...

Right-sizing treatment intensity in HER2-positive breast cancer

Oncotype DX: the genomic test that sharpens who needs chemotherapy

Basic breast cancer diagnostics are near-universal in Europe; advanced care is not

Daily mood and symptoms matter more than time living with the disease

Ultrasound screening: a two-year interval balances detection and recall burden

Molecular profiling of brain metastases changes systemic treatment

19 October, World Breast Cancer Day: what the evidence says about early detection

San Antonio hosts the world’s largest breast cancer research meeting in December

An analysis questions the risk-based screening endorsed by the WISDOM trial

Fragmented care marks the journey of women living with and beyond breast cancer

ESMO 2026 brings the global oncology community to Madrid on 23-27 October

Education and exercise help sustain breast cancer-specific quality of life in survivors

Immune and proliferation signatures point in opposite directions in stage I TNBC

Wider access to T-DM1 and pertuzumab could avert deaths from HER2+ cancer in Brazil

Supine MRI may reduce positive margins in breast-conserving surgery

Five-fraction breast radiotherapy: good tolerability and early tumour control

Neutrophil-to-lymphocyte ratio may predict pembrolizumab response in TNBC

A 50% oestrogen-receptor cutoff defines a poorly responding HER2+ subgroup

The gut microbiota-obesity axis in breast cancer: mechanisms and opportunities

De-escalating neoadjuvant therapy in HER2-positive breast cancer: who and how?

Oncomama
Oncomama

Papers de oncología de mama y avances de las unidades de mama en España

  • Diagnosis
    • Prevention & Screening
    • Breast Units
  • Treatment
    • Surgery & Reconstruction
  • Research
    • Meetings
    • Bibliomama Library
opciones
  • Diagnosis
    • Prevention & Screening
    • Breast Units
  • Treatment
    • Surgery & Reconstruction
  • Research
    • Meetings
    • Bibliomama Library
  • Breast Units
  • Treatment

Right-sizing treatment intensity in HER2-positive breast cancer

A Nature Reviews Clinical Oncology review examines how to escalate or de-escalate HER2-directed therapy across the disease continuum and which evidence gaps remain open....

oncomama
Nat Rev Clin OncolOctober 16, 2026
  • Research
  • Treatment

Oncotype DX: the genomic test that sharpens who needs chemotherapy

oncomama
Int J CancerOctober 16, 2026
  • Breast Units
  • Research

Basic breast cancer diagnostics are near-universal in Europe; advanced care is not

oncomama
BreastOctober 15, 2026
  • Research
  • Treatment

Daily mood and symptoms matter more than time living with the disease

oncomama
Cancer MedOctober 15, 2026
  • Breast Units
  • Prevention & Screening

Ultrasound screening: a two-year interval balances detection and recall burden

oncomama
Breast Cancer ResOctober 14, 2026
Molecular profiling of brain metastases changes systemic treatment
Int J CancerOctober 14, 2026
19 October, World Breast Cancer Day: what the evidence says about early detection
OMS / IARC / SEOMOctober 13, 2026
San Antonio hosts the world’s largest breast cancer research meeting in December
SABCS 2026October 13, 2026
An analysis questions the risk-based screening endorsed by the WISDOM trial
J Breast ImagingOctober 13, 2026
Fragmented care marks the journey of women living with and beyond breast cancer
Breast Cancer ResOctober 12, 2026
ESMO 2026 brings the global oncology community to Madrid on 23-27 October
ESMO 2026October 12, 2026
Copyright © 2026 | Powered by News Magazine X
oncomama  ·  oncohub  ·  disforia
Desarrollado por dosier.es y diseñado por marta ai